Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valcyte add-on therapy in CMV-positive glioblastoma after surgical resection
2006-002022-29Phase 2Completed
- Sponsor
- Karolinska Institutet, Center for Molecular medicine, L8:03 L8:03
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valganciclovir in glioblastoma (GBM) (2 arms), sponsored by Karolinska Institutet, Center for Molecular medicine, L8:03 L8:03. Primary endpoints: Tumor size by MRI at week 12 versus postoperative baseline and Tumor size by MRI at week 24 versus postoperative baseline. Started Jun 2006; status: completed.
02
Drugs
valganciclovir
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2006-002022-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002022-29.